<img height="1" width="1" src="https://www.facebook.com/tr?id=1475348972529988&amp;ev=PageView &amp;noscript=1">
Home
About
Why Milton Park?
Getting Here
Availability
News & Events
Work Here
Downloads
Contact Us

Immunocore Limited collaborate with MedImmune

Published on: 09/01/2014

Immunocore Limited, based at 57 Jubilee Avenue, yesterday announced their third major partnership agreement for Immunocore in the last six months, with MedImmune, the global biologics research and development arm of AstraZeneca. This follows major research and licensing agreements with Genetech and GlaxoSmithKline that took place in summer 2013.

Under the terms of the agreement, Immunocore and MedImmune will work together to generate ImmTACs against selected cancer targets. ImmTACs harness the power of the human immune system to control diseased cells that ordinarily escape immune recognition.

Immunocore will receive an upfront payment of $20 million per programme and the company is then eligible to receive up to $300 million in development and commercial milestone payments for each target programme and significant tiered royalties if the programmes are successful.

“We are delighted to be collaborating with MedImmune, a leader in the development of biotherapeutics with particular strengths in oncology,” said James Noble, Chief Executive Officer, Immunocore. “We look forward to working together to develop ImmTAC therapies against cancer targets and address the unmet medical needs of many thousands of cancer patients.”

Oncology is a core therapy area for AstraZeneca spanning both small molecule and biologics research and development. The company is developing a comprehensive portfolio in immune-mediated cancer therapies, and the collaboration with Immunocore will help expand MedImmune’s portfolio of agents that harness the patient’s own immune system to fight cancer in a very tumor-targeted way.

“We look forward to collaborating with Immunocore on this promising area of cancer research that has the potential to further enhance our immune-mediated cancer therapy portfolio for patients with a range of cancer types,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “Immunocore has a strong track record with its innovative ImmTAC technology, and presents a significant opportunity for us to achieve treatment breakthroughs in the area of immune-mediated cancer therapies.”

  All news stories

Got some news to share?

Tell us about your achievements and what you have been up to.
Submit a story

Submit News

Submission Terms and Conditions

Terms and conditions for submitting an event, news story or directory item onto Milton Park’s website: www.miltonpark.co.uk

  1. miltonpark.co.uk is owned and run by MEPC Ltd, owners and managers of Milton Park, Oxfordshire
  2. All submissions are forwarded to the Marketing Executive for approval before upload
  3. Content submitted may be subject to change
  4. Content must be written in good English and grammatically correct
  5. If the submission is not deemed suitable or relevant it will not be uploaded
  6. Content must be clear, easy to read, understandable and relevant to the occupiers of Milton Park
  7. Once uploaded, items are subject to deletion at any time
  8. Upon submission, you will receive a confirmation email with a copy of these terms and conditions for reference
  9. Upon submission, items will be uploaded within 3 working days if suitable
  10. Classifieds are deleted after six months of upload
  11. News stories are archived monthly and remain on the Website for one year
  12. Events are archived monthly and remain on the Website for one year
  13. Companies listed on the website will be removed when leaving Milton Park